Randomized phase III study of Erlotinib vs. observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: GCIG and EORTC-GCG study - Vergote, I (J Clin Oncol, 2012)
(suppl.): Abstract